Breaking Finance News

ValuEngine upgraded Amgen, Inc. (NASDAQ:AMGN) to Buy in a report released today.

Yesterday Amgen, Inc. (NASDAQ:AMGN) traded 0.19% higher at $171.72. The company’s 50-day moving average is $174.48 and its 200-day moving average is $167.49. The last stock close price is up 1.16% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 1,571,584 shares of the stock were exchanged, down from an average trading volume of 3,225,090

ValuEngine has upgraded Amgen, Inc. (NASDAQ:AMGN) to Buy in a report released on 07/06/2017.

See Chart Below

Amgen, Inc. (NASDAQ:AMGN)

Amgen, Inc. has a PE ratio of 15.43 with a one year low of $133.64 and a one year high of $184.21 AMGN’s total market value is presently $0.

In addition to ValuEngine reporting its stock price target, a total of 17 brokerages have issued a ratings update on the company. The average stock price target is $183.88 with 2 brokerages rating the stock a strong buy, 9 brokerages rating the stock a buy, 10 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Amgen, Inc. (NASDAQ:AMGN)

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.